Affinity Bio-Partner, a global clinical research organization dedicated to safe, ethical studies to ensure subjects benefit from the development of new and novel treatments and therapies, announced its launch a clinical trial for medical cannabis patients in Pennsylvania with diabetic nerve pain.

“I am very happy to have Dr. Bryan Doner and the Serena Group to work on this clinical trial. The future of medical cannabis and cannabinoids as medical treatments depends on properly conducted clinical trials, ”says Christina DiArcangelo, CEO of Affinity Bio Partners.

Those with diabetic nerve pain participating in the Pennsylvania Medical Cannabis Program can inquire about registration by calling 724-859-6200 or emailing

More content about cannabis in Spanish at El Planteo.

Courtesy photo.

© 2021 Benzinga does not offer investment advice. All rights reserved.